Department of Pharmaceutics, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium; Department Pulmonary Medicine, Tumor Immunology Laboratory, Ghent University, Ghent, Belgium.
J Control Release. 2018 Nov 10;289:125-145. doi: 10.1016/j.jconrel.2018.09.009. Epub 2018 Sep 14.
During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient's mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics.
在过去的十年中，抗肿瘤免疫疗法为有效对抗癌症进展开辟了新的机会。树突状细胞（DC）和嵌合抗原受体 T 细胞（CAR T）疗法的引入，以及基于抗体的免疫检查点抑制剂（CTLA-4、PD1 和 PDL1）的成功应用，推动了这一领域的发展，使许多患者受益。原位癌症疫苗接种是一种有吸引力的策略，可以进一步提高治疗效果，特别是针对患者的突变组，实现更个性化和个体化的免疫反应。基于纳米颗粒的递药平台可以辅助联合治疗，例如联合多种免疫刺激信号（PAMPs 和 DAMPs），以增加引发更广泛和全面的细胞毒性和记忆 T 细胞反应的可能性。在这篇综述中，讨论了癌症疫苗接种的各种方法和障碍，包括蓬勃发展的纳米颗粒设计和功能化领域的有益贡献，这可能进一步推动癌症免疫治疗的发展。
